{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Alzheimer\u2019s disease", "CBD", "Cannabis sativa", "cancer", "cannabidiol", "epilepsy", "mechanism of action", "multiple sclerosis", "pharmacological activity"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "33919010", "DateCompleted": {"Year": "2021", "Month": "05", "Day": "13"}, "DateRevised": {"Year": "2024", "Month": "04", "Day": "02"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "04", "Day": "21"}], "Language": ["eng"], "ELocationID": ["4294", "10.3390/ijms22094294"], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "22", "Issue": "9", "PubDate": {"Year": "2021", "Month": "Apr", "Day": "21"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action.", "Abstract": {"AbstractText": ["As the major nonpsychotropic constituent of <i>Cannabis sativa</i>, cannabidiol (CBD) is regarded as one of the most promising therapeutic agents due to its proven effectiveness in clinical trials for many human diseases. Due to the urgent need for more efficient pharmacological treatments for several chronic diseases, in this review, we discuss the potential beneficial effects of CBD for Alzheimer's disease, epilepsy, multiple sclerosis, and neurological cancers. Due to its wide range of pharmacological activities (e.g., antioxidant, anti-inflammatory, and neuroprotective properties), CBD is considered a multimodal drug for the treatment of a range of neurodegenerative disorders, and various cancer types, including neoplasms of the neural system. The different mechanisms of action of CBD are here disclosed, together with recent progress in the use of this cannabis-derived constituent as a new therapeutic approach."]}, "AuthorList": [{"Identifier": ["0000-0003-2305-3116"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biotechnology, Institute of Natural Fibres and Medicinal Plants-State Research Institute, Wojska Polskiego 71B, 60-630 Pozna\u0144, Poland."}], "LastName": "O\u017carowski", "ForeName": "Marcin", "Initials": "M"}, {"Identifier": ["0000-0001-6599-9204"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chair and Department of Medical Microbiology, Pozna\u0144 University of Medical Sciences, Wieniawskiego 3, 61-712 Pozna\u0144, Poland."}], "LastName": "Karpi\u0144ski", "ForeName": "Tomasz M", "Initials": "TM"}, {"Identifier": ["0000-0003-2603-1377"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Human Genetics, Polish Academy of Sciences, Strzeszy\u0144ska 32, 60-479 Pozna\u0144, Poland."}, {"Identifier": [], "Affiliation": "Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, P\u00f3lo das Ci\u00eancias da Sa\u00fade, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal."}], "LastName": "Zieli\u0144ska", "ForeName": "Aleksandra", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, P\u00f3lo das Ci\u00eancias da Sa\u00fade, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal."}, {"Identifier": [], "Affiliation": "CEB-Center of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal."}], "LastName": "Souto", "ForeName": "Eliana B", "Initials": "EB"}, {"Identifier": ["0000-0003-0629-2991"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biotechnology, Institute of Natural Fibres and Medicinal Plants-State Research Institute, Wojska Polskiego 71B, 60-630 Pozna\u0144, Poland."}], "LastName": "Wielgus", "ForeName": "Karolina", "Initials": "K"}], "GrantList": [{"GrantID": "ONKOKAN, INNOMED/I/11/NCBR/2014", "Agency": "National Centre for Research and Development", "Country": ""}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anticonvulsants"}, {"RegistryNumber": "19GBJ60SN5", "NameOfSubstance": "Cannabidiol"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Anticonvulsants"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Cannabidiol"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Neoplasms"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Nervous System Diseases"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Makowiecka J., Wielgus K. Therapeutic Potential of Cannabinoids\u2014Retrospective and Historical Developments. J. Nat. Fibers. 2014;11:185\u2013198. doi: 10.1080/15440478.2013.861782.", "ArticleIdList": ["10.1080/15440478.2013.861782"]}, {"Citation": "Makowiecka J., Wielgus K. Therapeutic Potential of Cannabinoids\u2014Perspectives for the Future. J. Nat. Fibers. 2014;11:283\u2013311. doi: 10.1080/15440478.2013.878604.", "ArticleIdList": ["10.1080/15440478.2013.878604"]}, {"Citation": "Pertwee R.G. Cannabinoid pharmacology: The first 66 years. Br. J. Pharmacol. 2006;147:S163\u2013S171. doi: 10.1038/sj.bjp.0706406.", "ArticleIdList": ["10.1038/sj.bjp.0706406", "PMC1760722", "16402100"]}, {"Citation": "di Giacomo V., Chiavaroli A., Recinella L., Orlando G., Cataldi A., Rapino M., Di Valerio V., Ronci M., Leone S., Brunetti L., et al. Antioxidant and Neuroprotective Effects Induced by Cannabidiol and Cannabigerol in Rat CTX-TNA2 Astrocytes and Isolated Cortexes. Int. J. Mol. Sci. 2020;21:3575. doi: 10.3390/ijms21103575.", "ArticleIdList": ["10.3390/ijms21103575", "PMC7279038", "32443623"]}, {"Citation": "Silvestro S., Mammana S., Cavalli E., Bramanti P., Mazzon E. Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials. Molecules. 2019;24:1459. doi: 10.3390/molecules24081459.", "ArticleIdList": ["10.3390/molecules24081459", "PMC6514832", "31013866"]}, {"Citation": "Atalay S., Jarocka-Karpowicz I., Skrzydlewska E. Antioxidative and Anti-Inflammatory Properties of Cannabidiol. Antioxidants. 2019;9:21. doi: 10.3390/antiox9010021.", "ArticleIdList": ["10.3390/antiox9010021", "PMC7023045", "31881765"]}, {"Citation": "Shrader S.H., Tong Y.-G., Duff M.B., Freedman J.H., Song Z.-H. Involvement of dopamine receptor in the actions of non-psychoactive phytocannabinoids. Biochem. Biophys. Res. Commun. 2020;533:1366\u20131370. doi: 10.1016/j.bbrc.2020.10.021.", "ArticleIdList": ["10.1016/j.bbrc.2020.10.021", "PMC7744432", "33097185"]}, {"Citation": "Fern\u00e1ndez-Ruiz J., Sagredo O., Pazos M.R., Garc\u00eda C., Pertwee R., Mechoulam R., Mart\u00ednez-Orgado J. Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid? Br. J. Clin. Pharmacol. 2013;75:323\u2013333. doi: 10.1111/j.1365-2125.2012.04341.x.", "ArticleIdList": ["10.1111/j.1365-2125.2012.04341.x", "PMC3579248", "22625422"]}, {"Citation": "Watt G., Karl T. In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer\u2019s Disease. Front. Pharmacol. 2017;8 doi: 10.3389/fphar.2017.00020.", "ArticleIdList": ["10.3389/fphar.2017.00020", "PMC5289988", "28217094"]}, {"Citation": "Vall\u00e9e A., Lecarpentier Y., Guillevin R., Vall\u00e9e J.-N. Effects of cannabidiol interactions with Wnt/\u03b2-catenin pathway and PPAR\u03b3 on oxidative stress and neuroinflammation in Alzheimer\u2019s disease. Acta Biochim. Biophys. Sin. 2017;49:853\u2013866. doi: 10.1093/abbs/gmx073.", "ArticleIdList": ["10.1093/abbs/gmx073", "28981597"]}, {"Citation": "Furqan T., Batool S., Habib R., Shah M., Kalasz H., Darvas F., Kuca K., Nepovimova E., Batool S., Nurulain S.M. Cannabis Constituents and Acetylcholinesterase Interaction: Molecular Docking, In Vitro Studies and Association with CNR1 rs806368 and ACHE rs17228602. Biomolecules. 2020;10:758. doi: 10.3390/biom10050758.", "ArticleIdList": ["10.3390/biom10050758", "PMC7277636", "32414087"]}, {"Citation": "Scuderi C., Steardo L., Esposito G. Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5Y APP+ Cells Through PPAR\u03b3 Involvement. Phyther. Res. 2014;28:1007\u20131013. doi: 10.1002/ptr.5095.", "ArticleIdList": ["10.1002/ptr.5095", "24288245"]}, {"Citation": "Hao F., Feng Y. Cannabidiol (CBD) enhanced the hippocampal immune response and autophagy of APP/PS1 Alzheimer\u2019s mice uncovered by RNA-seq. Life Sci. 2021;264:118624. doi: 10.1016/j.lfs.2020.118624.", "ArticleIdList": ["10.1016/j.lfs.2020.118624", "33096116"]}, {"Citation": "Hughes B., Herron C.E. Cannabidiol Reverses Deficits in Hippocampal LTP in a Model of Alzheimer\u2019s Disease. Neurochem. Res. 2019;44:703\u2013713. doi: 10.1007/s11064-018-2513-z.", "ArticleIdList": ["10.1007/s11064-018-2513-z", "29574668"]}, {"Citation": "Juknat A., Gao F., Coppola G., Vogel Z., Kozela E. miRNA expression profiles and molecular networks in resting and LPS-activated BV-2 microglia\u2014Effect of cannabinoids. PLoS ONE. 2019;14:e0212039. doi: 10.1371/journal.pone.0212039.", "ArticleIdList": ["10.1371/journal.pone.0212039", "PMC6370221", "30742662"]}, {"Citation": "Ibeas Bih C., Chen T., Nunn A.V.W., Bazelot M., Dallas M., Whalley B.J. Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics. 2015;12:699\u2013730. doi: 10.1007/s13311-015-0377-3.", "ArticleIdList": ["10.1007/s13311-015-0377-3", "PMC4604182", "26264914"]}, {"Citation": "Desvergne B., Wahli W. Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*. Endocr. Rev. 1999;20:649\u2013688. doi: 10.1210/edrv.20.5.0380.", "ArticleIdList": ["10.1210/edrv.20.5.0380", "10529898"]}, {"Citation": "O\u2019Sullivan S.E., Sun Y., Bennett A.J., Randall M.D., Kendall D.A. Time-dependent vascular actions of cannabidiol in the rat aorta. Eur. J. Pharmacol. 2009;612:61\u201368. doi: 10.1016/j.ejphar.2009.03.010.", "ArticleIdList": ["10.1016/j.ejphar.2009.03.010", "19285060"]}, {"Citation": "Jiang Q., Heneka M., Landreth G.E. The Role of Peroxisome Proliferator-Activated Receptor-\u03b3 (PPAR\u03b3) in Alzheimer\u2019s Disease. CNS Drugs. 2008;22:1\u201314. doi: 10.2165/00023210-200822010-00001.", "ArticleIdList": ["10.2165/00023210-200822010-00001", "18072811"]}, {"Citation": "Camacho I.E. Peroxisome Proliferator-Activated Receptor Induces a Clearance Mechanism for the Amyloid-Peptide. J. Neurosci. 2004;24:10908\u201310917. doi: 10.1523/JNEUROSCI.3987-04.2004.", "ArticleIdList": ["10.1523/JNEUROSCI.3987-04.2004", "PMC6730204", "15574741"]}, {"Citation": "Esposito G., Scuderi C., Valenza M., Togna G.I., Latina V., De Filippis D., Cipriano M., Carrat\u00f9 M.R., Iuvone T., Steardo L. Cannabidiol Reduces A\u03b2-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPAR\u03b3 Involvement. PLoS ONE. 2011;6:e28668. doi: 10.1371/journal.pone.0028668.", "ArticleIdList": ["10.1371/journal.pone.0028668", "PMC3230631", "22163051"]}, {"Citation": "Abdel-Salam O.M.E., Youness E.R., Khadrawy Y.A., Sleem A.A. Acetylcholinesterase, butyrylcholinesterase and paraoxonase 1 activities in rats treated with cannabis, tramadol or both. Asian Pac. J. Trop. Med. 2016;9:1089\u20131094. doi: 10.1016/j.apjtm.2016.09.009.", "ArticleIdList": ["10.1016/j.apjtm.2016.09.009", "27890370"]}, {"Citation": "Abdel-Salam O.M.E., Khadrawy Y.A. The Inhibition of Serum Cholinesterases by Cannabis sativa and/or Tramadol. J. Neurol. Forecast. 2019;2:1\u20134."}, {"Citation": "Smeriglio A., Trombetta D., Alloisio S., Cornara L., Denaro M., Garbati P., Grassi G., Circosta C. Promising in vitro antioxidant, anti-acetylcholinesterase and neuroactive effects of essential oil from two non-psychotropic Cannabis sativa L. biotypes. Phyther. Res. 2020;34:2287\u20132302. doi: 10.1002/ptr.6678.", "ArticleIdList": ["10.1002/ptr.6678", "32309898"]}, {"Citation": "Karimi I., Yousofvand N., Hussein B.A. In vitro cholinesterase inhibitory action of Cannabis sativa L. Cannabaceae and in silico study of its selected phytocompounds. Silico Pharmacol. 2021;9:13. doi: 10.1007/s40203-021-00075-0.", "ArticleIdList": ["10.1007/s40203-021-00075-0", "PMC7820056", "33520592"]}, {"Citation": "Murillo-Rodr\u00edguez E., Arankowsky-Sandoval G., Rocha N.B., Peniche-Amante R., Veras A.B., Machado S., Budde H. Systemic Injections of Cannabidiol Enhance Acetylcholine Levels from Basal Forebrain in Rats. Neurochem. Res. 2018;43:1511\u20131518. doi: 10.1007/s11064-018-2565-0.", "ArticleIdList": ["10.1007/s11064-018-2565-0", "29876791"]}, {"Citation": "Miller L.L., Branconnier R.J. Cannabis: Effects on memory and the cholinergic limbic system. Psychol. Bull. 1983;93:441\u2013456. doi: 10.1037/0033-2909.93.3.441.", "ArticleIdList": ["10.1037/0033-2909.93.3.441", "6306710"]}, {"Citation": "Greig N.H., Lahiri D.K., Sambamurti K. Butyrylcholinesterase: An Important New Target in Alzheimer\u2019s Disease Therapy. Int. Psychogeriatr. 2002;14:77\u201391. doi: 10.1017/S1041610203008676.", "ArticleIdList": ["10.1017/S1041610203008676", "12636181"]}, {"Citation": "Jimenez Naranjo C., Osborne A.L., Weston-Green K. Effect of cannabidiol on muscarinic neurotransmission in the pre-frontal cortex and hippocampus of the poly I:C rat model of schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2019;94:109640. doi: 10.1016/j.pnpbp.2019.109640.", "ArticleIdList": ["10.1016/j.pnpbp.2019.109640", "31108177"]}, {"Citation": "Tripathi H.L., Vocci F.J., Brase D.A., Dewey W.L. Effects of cannabinoids on levels of acetylcholine and choline and on turnover rate of acetylcholine in various regions of the mouse brain. Alcohol Drug Res. 1987;7:525\u2013532.", "ArticleIdList": ["3620017"]}, {"Citation": "da Silva V.K., de Freitas B.S., Garcia R.C.L., Monteiro R.T., Hallak J.E., Zuardi A.W., Crippa J.A.S., Schr\u00f6der N. Antiapoptotic effects of cannabidiol in an experimental model of cognitive decline induced by brain iron overload. Transl. Psychiatry. 2018;8:176. doi: 10.1038/s41398-018-0232-5.", "ArticleIdList": ["10.1038/s41398-018-0232-5", "PMC6120904", "30177808"]}, {"Citation": "Mahmoud El-Desouki R.K. New insights on Alzheimer\u2019s disease. J. Microsc. Ultrastruct. 2014;2:57. doi: 10.1016/j.jmau.2014.01.002.", "ArticleIdList": ["10.1016/j.jmau.2014.01.002"]}, {"Citation": "Podtelezhnikov A.A., Tanis K.Q., Nebozhyn M., Ray W.J., Stone D.J., Loboda A.P. Molecular Insights into the Pathogenesis of Alzheimer\u2019s Disease and Its Relationship to Normal Aging. PLoS ONE. 2011;6:e29610. doi: 10.1371/journal.pone.0029610.", "ArticleIdList": ["10.1371/journal.pone.0029610", "PMC3247273", "22216330"]}, {"Citation": "Armstrong R. Cortical laminar distribution of \u03b2-amyloid deposits in five neurodegenerative disorders. Folia Neuropathol. 2020;58:1\u20139. doi: 10.5114/fn.2020.94001.", "ArticleIdList": ["10.5114/fn.2020.94001", "32337952"]}, {"Citation": "Cooray R., Gupta V., Suphioglu C. Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson\u2019s and Alzheimer\u2019s Diseases: A Review. Mol. Neurobiol. 2020;57:4878\u20134890. doi: 10.1007/s12035-020-02054-6.", "ArticleIdList": ["10.1007/s12035-020-02054-6", "PMC7515854", "32813239"]}, {"Citation": "Karl T., Garner B., Cheng D. The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer\u2019s disease. Behav. Pharmacol. 2017;28:142\u2013160. doi: 10.1097/FBP.0000000000000247.", "ArticleIdList": ["10.1097/FBP.0000000000000247", "27471947"]}, {"Citation": "Janefjord E., M\u00e5\u00e5g J.L.V., Harvey B.S., Smid S.D. Cannabinoid Effects on \u03b2 Amyloid Fibril and Aggregate Formation, Neuronal and Microglial-Activated Neurotoxicity In Vitro. Cell. Mol. Neurobiol. 2014;34:31\u201342. doi: 10.1007/s10571-013-9984-x.", "ArticleIdList": ["10.1007/s10571-013-9984-x", "24030360"]}, {"Citation": "Esposito G., Scuderi C., Savani C., Steardo L., De Filippis D., Cottone P., Iuvone T., Cuomo V., Steardo L. Cannabidiol in vivo blunts \u03b2-amyloid induced neuroinflammation by suppressing IL-1\u03b2 and iNOS expression. Br. J. Pharmacol. 2007;151:1272\u20131279. doi: 10.1038/sj.bjp.0707337.", "ArticleIdList": ["10.1038/sj.bjp.0707337", "PMC2189818", "17592514"]}, {"Citation": "Esposito G., De Filippis D., Carnuccio R., Izzo A.A., Iuvone T. The marijuana component cannabidiol inhibits \u03b2-amyloid-induced tau protein hyperphosphorylation through Wnt/\u03b2-catenin pathway rescue in PC12 cells. J. Mol. Med. 2006;84:253\u2013258. doi: 10.1007/s00109-005-0025-1.", "ArticleIdList": ["10.1007/s00109-005-0025-1", "16389547"]}, {"Citation": "Esposito G., De Filippis D., Maiuri M.C., De Stefano D., Carnuccio R., Iuvone T. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in \u03b2-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-\u03baB involvement. Neurosci. Lett. 2006;399:91\u201395. doi: 10.1016/j.neulet.2006.01.047.", "ArticleIdList": ["10.1016/j.neulet.2006.01.047", "16490313"]}, {"Citation": "Mart\u00edn-Moreno A.M., Reigada D., Ram\u00edrez B.G., Mechoulam R., Innamorato N., Cuadrado A., de Ceballos M.L. Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo: Relevance to Alzheimer\u2019s Disease. Mol. Pharmacol. 2011;79:964\u2013973. doi: 10.1124/mol.111.071290.", "ArticleIdList": ["10.1124/mol.111.071290", "PMC3102548", "21350020"]}, {"Citation": "Ramirez B.G. Prevention of Alzheimer\u2019s Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation. J. Neurosci. 2005;25:1904\u20131913. doi: 10.1523/JNEUROSCI.4540-04.2005.", "ArticleIdList": ["10.1523/JNEUROSCI.4540-04.2005", "PMC6726060", "15728830"]}, {"Citation": "Fisher R.S., Acevedo C., Arzimanoglou A., Bogacz A., Cross J.H., Elger C.E., Engel J., Forsgren L., French J.A., Glynn M., et al. ILAE Official Report: A practical clinical definition of epilepsy. Epilepsia. 2014;55:475\u2013482. doi: 10.1111/epi.12550.", "ArticleIdList": ["10.1111/epi.12550", "24730690"]}, {"Citation": "Schmidt D., Schachter S.C. Drug treatment of epilepsy in adults. BMJ. 2014;348:g254. doi: 10.1136/bmj.g254.", "ArticleIdList": ["10.1136/bmj.g254", "24583319"]}, {"Citation": "Nabbout R., Thiele E.A. The role of cannabinoids in epilepsy treatment: A critical review of efficacy results from clinical trials. Epileptic Disord. 2020;22:23\u201328.", "ArticleIdList": ["31916540"]}, {"Citation": "Rubin R. The Path to the First FDA-Approved Cannabis-Derived Treatment and What Comes Next. JAMA. 2018;320:1227. doi: 10.1001/jama.2018.11914.", "ArticleIdList": ["10.1001/jama.2018.11914", "30193358"]}, {"Citation": "Furgiuele A., Cosentino M., Ferrari M., Marino F. Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: A Systematic Review. J. Neuroimmune Pharmacol. 2021 doi: 10.1007/s11481-021-09982-7.", "ArticleIdList": ["10.1007/s11481-021-09982-7", "PMC7829325", "33492630"]}, {"Citation": "Devinsky O., Marsh E., Friedman D., Thiele E., Laux L., Sullivan J., Miller I., Flamini R., Wilfong A., Filloux F., et al. Cannabidiol in patients with treatment-resistant epilepsy: An open-label interventional trial. Lancet Neurol. 2016;15:270\u2013278. doi: 10.1016/S1474-4422(15)00379-8.", "ArticleIdList": ["10.1016/S1474-4422(15)00379-8", "26724101"]}, {"Citation": "Devinsky O., Patel A.D., Thiele E.A., Wong M.H., Appleton R., Harden C.L., Greenwood S., Morrison G., Sommerville K. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90:e1204\u2013e1211. doi: 10.1212/WNL.0000000000005254.", "ArticleIdList": ["10.1212/WNL.0000000000005254", "PMC5890607", "29540584"]}, {"Citation": "Devinsky O., Cross J.H., Laux L., Marsh E., Miller I., Nabbout R., Scheffer I.E., Thiele E.A., Wright S. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N. Engl. J. Med. 2017;376:2011\u20132020. doi: 10.1056/NEJMoa1611618.", "ArticleIdList": ["10.1056/NEJMoa1611618", "28538134"]}, {"Citation": "Bialer M., Perucca E. Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials. Epilepsia. 2020;61:1082\u20131089. doi: 10.1111/epi.16542.", "ArticleIdList": ["10.1111/epi.16542", "32452568"]}, {"Citation": "Lipnik-\u0160tangelj M., Razinger B. A regulatory take on cannabis and cannabinoids for medicinal use in the European Union. Arch. Ind. Hyg. Toxicol. 2020;71:12\u201318. doi: 10.2478/aiht-2020-71-3302.", "ArticleIdList": ["10.2478/aiht-2020-71-3302", "PMC7837236", "32597142"]}, {"Citation": "Perucca E. Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last? J. Epilepsy Res. 2017;7:61\u201376. doi: 10.14581/jer.17012.", "ArticleIdList": ["10.14581/jer.17012", "PMC5767492", "29344464"]}, {"Citation": "Devinsky O., Cilio M.R., Cross H., Fernandez-Ruiz J., French J., Hill C., Katz R., Di Marzo V., Jutras-Aswad D., Notcutt W.G., et al. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55:791\u2013802. doi: 10.1111/epi.12631.", "ArticleIdList": ["10.1111/epi.12631", "PMC4707667", "24854329"]}, {"Citation": "Hawksworth G., McArdle K. In: Metabolism and Pharmacokinetics of Cannabinoids. The Medicinal Uses of Cannabis and Cannabinoids. Guy G.W., Whittle B.A., Robson P.J., editors. Pharmaceutical Press; London, UK: 2004."}, {"Citation": "Lodzki M., Godin B., Rakou L., Mechoulam R., Gallily R., Touitou E. Cannabidiol\u2014transdermal delivery and anti-inflammatory effect in a murine model. J. Control. Release. 2003;93:377\u2013387. doi: 10.1016/j.jconrel.2003.09.001.", "ArticleIdList": ["10.1016/j.jconrel.2003.09.001", "14644587"]}, {"Citation": "Pagano S., Coniglio M., Valenti C., Federici M.I., Lombardo G., Cianetti S., Marinucci L. Biological effects of Cannabidiol on normal human healthy cell populations: Systematic review of the literature. Biomed. Pharmacother. 2020;132:110728. doi: 10.1016/j.biopha.2020.110728.", "ArticleIdList": ["10.1016/j.biopha.2020.110728", "33038581"]}, {"Citation": "Klein B.D., Jacobson C.A., Metcalf C.S., Smith M.D., Wilcox K.S., Hampson A.J., Kehne J.H. Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP) Neurochem. Res. 2017;42:1939\u20131948. doi: 10.1007/s11064-017-2287-8.", "ArticleIdList": ["10.1007/s11064-017-2287-8", "28478594"]}, {"Citation": "Gray R.A., Whalley B.J. The proposed mechanisms of action of CBD in epilepsy. Epileptic Disord. 2020;22:S10\u2013S15. doi: 10.1684/epd.2020.1135.", "ArticleIdList": ["10.1684/epd.2020.1135", "32053110"]}, {"Citation": "dos Santos R.G., Hallak J.E.C., Leite J.P., Zuardi A.W., Crippa J.A.S. Phytocannabinoids and epilepsy. J. Clin. Pharm. Ther. 2015;40:135\u2013143. doi: 10.1111/jcpt.12235.", "ArticleIdList": ["10.1111/jcpt.12235", "25475762"]}, {"Citation": "Marichal-Cancino B.A., Fajardo-Valdez A., Ruiz-Contreras A.E., Mendez-D\u00edaz M., Prospero-Garc\u00eda O. Advances in the Physiology of GPR55 in the Central Nervous System. Curr. Neuropharmacol. 2017;15 doi: 10.2174/1570159X14666160729155441.", "ArticleIdList": ["10.2174/1570159X14666160729155441", "PMC5771053", "27488130"]}, {"Citation": "Lazarini-Lopes W., Do Val-da Silva R.A., da Silva-J\u00fanior R.M.P., Leite J.P., Garcia-Cairasco N. The anticonvulsant effects of cannabidiol in experimental models of epileptic seizures: From behavior and mechanisms to clinical insights. Neurosci. Biobehav. Rev. 2020;111:166\u2013182. doi: 10.1016/j.neubiorev.2020.01.014.", "ArticleIdList": ["10.1016/j.neubiorev.2020.01.014", "31954723"]}, {"Citation": "Bakas T., van Nieuwenhuijzen P.S., Devenish S.O., McGregor I.S., Arnold J.C., Chebib M. The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA A receptors. Pharmacol. Res. 2017;119:358\u2013370. doi: 10.1016/j.phrs.2017.02.022.", "ArticleIdList": ["10.1016/j.phrs.2017.02.022", "28249817"]}, {"Citation": "Cifelli P., Ruffolo G., De Felice E., Alfano V., van Vliet E.A., Aronica E., Palma E. Phytocannabinoids in Neurological Diseases: Could They Restore a Physiological GABAergic Transmission? Int. J. Mol. Sci. 2020;21:723. doi: 10.3390/ijms21030723.", "ArticleIdList": ["10.3390/ijms21030723", "PMC7038116", "31979108"]}, {"Citation": "Rosenberg E.C., Tsien R.W., Whalley B.J., Devinsky O. Cannabinoids and Epilepsy. Neurotherapeutics. 2015;12:747\u2013768. doi: 10.1007/s13311-015-0375-5.", "ArticleIdList": ["10.1007/s13311-015-0375-5", "PMC4604191", "26282273"]}, {"Citation": "Kwan Cheung K.A., Peiris H., Wallace G., Holland O.J., Mitchell M.D. The Interplay between the Endocannabinoid System, Epilepsy and Cannabinoids. Int. J. Mol. Sci. 2019;20:6079. doi: 10.3390/ijms20236079.", "ArticleIdList": ["10.3390/ijms20236079", "PMC6929011", "31810321"]}, {"Citation": "Gloss D., Vickrey B. Cannabinoids for epilepsy. In: Gloss D., editor. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd; Chichester, UK: 2011."}, {"Citation": "Hachinski V., Iadecola C., Petersen R.C., Breteler M.M., Nyenhuis D.L., Black S.E., Powers W.J., DeCarli C., Merino J.G., Kalaria R.N., et al. National Institute of Neurological Disorders and Stroke\u2013Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards. Stroke. 2006;37:2220\u20132241. doi: 10.1161/01.STR.0000237236.88823.47.", "ArticleIdList": ["10.1161/01.STR.0000237236.88823.47", "16917086"]}, {"Citation": "Bhattacharya A., Mishra R., Tiwari P. Multiple sclerosis: An overview. Asian Pac. J. Trop. Biomed. 2012;2:S1954\u2013S1962. doi: 10.1016/S2221-1691(12)60525-5.", "ArticleIdList": ["10.1016/S2221-1691(12)60525-5"]}, {"Citation": "Bertelson J., Price B. In: Depression and Psychosis in Neurological Practice. Neurology in Clinical Practice: Principles of Diagnosis and Management. Bradley W.G., Daroff R.B., Fenichel G.M., Jankovic J., editors. Butterworth-Heinemann; Philadelphia, PA, USA: 2004."}, {"Citation": "Mecha M., Feli\u00fa A., Carrillo-Salinas F.J., Guaza C. Handbook of Cannabis and Related Pathologies. Elsevier; Amsterdam, The Netherlands: 2017. Cannabidiol and Multiple Sclerosis; pp. 893\u2013904."}, {"Citation": "Leussink V.I., Husseini L., Warnke C., Broussalis E., Hartung H.-P., Kieseier B.C. Symptomatic therapy in multiple sclerosis: The role of cannabinoids in treating spasticity. Ther. Adv. Neurol. Disord. 2012;5:255\u2013266. doi: 10.1177/1756285612453972.", "ArticleIdList": ["10.1177/1756285612453972", "PMC3437528", "22973422"]}, {"Citation": "de Lago E., G\u00f3mez-Ruiz M., Moreno-Martet M., Fern\u00e1ndez-Ruiz J. Cannabinoids, multiple sclerosis and neuroprotection. Expert Rev. Clin. Pharmacol. 2009;2:645\u2013660. doi: 10.1586/ecp.09.42.", "ArticleIdList": ["10.1586/ecp.09.42", "22112258"]}, {"Citation": "Filippini G., Lasserson T., Dwan K., Borrelli F., Izzo A., Minozzi S. Cannabis and cannabinoids for people with multiple sclerosis. Cochrane Database Syst. Rev. 2019;2019 doi: 10.1002/14651858.CD013444.", "ArticleIdList": ["10.1002/14651858.CD013444", "PMC9069991", "35510826"]}, {"Citation": "Australian Government Guidance for the Use of Medicinal Cannabis in the Treatment of Multiple Sclerosis in Australia.  [(accessed on 15 May 2019)]; Available online:  https://www.tga.gov.au/publication/guidance-use-medicinal-cannabis-treatment-multiple-sclerosis-australia."}, {"Citation": "Jones \u00c9., Vlachou S. A Critical Review of the Role of the Cannabinoid Compounds \u03949-Tetrahydrocannabinol (\u03949-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment. Molecules. 2020;25:4930. doi: 10.3390/molecules25214930.", "ArticleIdList": ["10.3390/molecules25214930", "PMC7663366", "33113776"]}, {"Citation": "Elliott D.M., Singh N., Nagarkatti M., Nagarkatti P.S. Cannabidiol Attenuates Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis Through Induction of Myeloid-Derived Suppressor Cells. Front. Immunol. 2018;9 doi: 10.3389/fimmu.2018.01782.", "ArticleIdList": ["10.3389/fimmu.2018.01782", "PMC6085417", "30123217"]}, {"Citation": "Nichols J.M., Kummari E., Sherman J., Yang E.-J., Dhital S., Gilfeather C., Yray G., Morgan T., Kaplan B.L.F. CBD Suppression of EAE Is Correlated with Early Inhibition of Splenic IFN-\u03b3 + CD8+ T Cells and Modest Inhibition of Neuroinflammation. J. Neuroimmune Pharmacol. 2020 doi: 10.1007/s11481-020-09917-8.", "ArticleIdList": ["10.1007/s11481-020-09917-8", "PMC7679272", "32440886"]}, {"Citation": "Yadav V., Bever C., Bowen J., Bowling A., Weinstock-Guttman B., Cameron M., Bourdette D., Gronseth G.S., Narayanaswami P. Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82:1083\u20131092. doi: 10.1212/WNL.0000000000000250.", "ArticleIdList": ["10.1212/WNL.0000000000000250", "PMC3962995", "24663230"]}, {"Citation": "Schabas A., Vukojevic V., Taylor C., Thu Z., Badyal A., Chan J., Devonshire V., Traboulsee A., Sayao A., Carruthers R. Cannabis-based product use in a multiple sclerosis cohort. Mult. Scler. J. Exp. Transl. Clin. 2019;5:205521731986936. doi: 10.1177/2055217319869360.", "ArticleIdList": ["10.1177/2055217319869360", "PMC6764052", "31598330"]}, {"Citation": "Banwell E., Pavisian B., Lee L., Feinstein A. Attitudes to cannabis and patterns of use among Canadians with multiple sclerosis. Mult. Scler. Relat. Disord. 2016;10:123\u2013126. doi: 10.1016/j.msard.2016.09.008.", "ArticleIdList": ["10.1016/j.msard.2016.09.008", "27919478"]}, {"Citation": "Anis O., Vinayaka A.C., Shalev N., Namdar D., Nadarajan S., Anil S.M., Cohen O., Belausov E., Ramon J., Mayzlish Gati E., et al. Cannabis-Derived Compounds Cannabichromene and \u03949-Tetrahydrocannabinol Interact and Exhibit Cytotoxic Activity against Urothelial Cell Carcinoma Correlated with Inhibition of Cell Migration and Cytoskeleton Organization. Molecules. 2021;26:465. doi: 10.3390/molecules26020465.", "ArticleIdList": ["10.3390/molecules26020465", "PMC7830447", "33477303"]}, {"Citation": "Go Y.Y., Kim S.R., Kim D.Y., Chae S.-W., Song J.-J. Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci. Rep. 2020;10:20622. doi: 10.1038/s41598-020-77674-y.", "ArticleIdList": ["10.1038/s41598-020-77674-y", "PMC7692486", "33244087"]}, {"Citation": "Fisher T., Golan H., Schiby G., PriChen S., Smoum R., Moshe I., Peshes-Yaloz N., Castiel A., Waldman D., Gallily R., et al. In Vitro and In Vivo Efficacy of Non-Psychoactive Cannabidiol in Neuroblastoma. Curr. Oncol. 2016;23:15\u201322. doi: 10.3747/co.23.2893.", "ArticleIdList": ["10.3747/co.23.2893", "PMC4791143", "27022310"]}, {"Citation": "Vaccani A., Massi P., Colombo A., Rubino T., Parolaro D. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br. J. Pharmacol. 2005;144:1032\u20131036. doi: 10.1038/sj.bjp.0706134.", "ArticleIdList": ["10.1038/sj.bjp.0706134", "PMC1576089", "15700028"]}, {"Citation": "Marinelli O., Morelli M.B., Annibali D., Aguzzi C., Zeppa L., Tuyaerts S., Amantini C., Amant F., Ferretti B., Maggi F., et al. The Effects of Cannabidiol and Prognostic Role of TRPV2 in Human Endometrial Cancer. Int. J. Mol. Sci. 2020;21:5409. doi: 10.3390/ijms21155409.", "ArticleIdList": ["10.3390/ijms21155409", "PMC7432565", "32751388"]}, {"Citation": "Jeong S., Jo M.J., Yun H.K., Kim D.Y., Kim B.R., Kim J.L., Park S.H., Na Y.J., Jeong Y.A., Kim B.G., et al. Cannabidiol promotes apoptosis via regulation of XIAP/Smac in gastric cancer. Cell Death Dis. 2019;10:846. doi: 10.1038/s41419-019-2001-7.", "ArticleIdList": ["10.1038/s41419-019-2001-7", "PMC6838113", "31699976"]}, {"Citation": "Solinas M., Massi P., Cantelmo A., Cattaneo M., Cammarota R., Bartolini D., Cinquina V., Valenti M., Vicentini L., Noonan D., et al. Cannabidiol inhibits angiogenesis by multiple mechanisms. Br. J. Pharmacol. 2012;167:1218\u20131231. doi: 10.1111/j.1476-5381.2012.02050.x.", "ArticleIdList": ["10.1111/j.1476-5381.2012.02050.x", "PMC3504989", "22624859"]}, {"Citation": "Shrivastava A., Kuzontkoski P.M., Groopman J.E., Prasad A. Cannabidiol Induces Programmed Cell Death in Breast Cancer Cells by Coordinating the Cross-talk between Apoptosis and Autophagy. Mol. Cancer Ther. 2011;10:1161\u20131172. doi: 10.1158/1535-7163.MCT-10-1100.", "ArticleIdList": ["10.1158/1535-7163.MCT-10-1100", "21566064"]}, {"Citation": "Olivas-Aguirre M., Torres-L\u00f3pez L., Valle-Reyes J.S., Hern\u00e1ndez-Cruz A., Pottosin I., Dobrovinskaya O. Cannabidiol directly targets mitochondria and disturbs calcium homeostasis in acute lymphoblastic leukemia. Cell Death Dis. 2019;10:779. doi: 10.1038/s41419-019-2024-0.", "ArticleIdList": ["10.1038/s41419-019-2024-0", "PMC6791884", "31611561"]}, {"Citation": "Olivas-Aguirre M., Torres-L\u00f3pez L., Pottosin I., Dobrovinskaya O. Phenolic Compounds Cannabidiol, Curcumin and Quercetin Cause Mitochondrial Dysfunction and Suppress Acute Lymphoblastic Leukemia Cells. Int. J. Mol. Sci. 2020;22:204. doi: 10.3390/ijms22010204.", "ArticleIdList": ["10.3390/ijms22010204", "PMC7795267", "33379175"]}, {"Citation": "Jeong S., Yun H.K., Jeong Y.A., Jo M.J., Kang S.H., Kim J.L., Kim D.Y., Park S.H., Kim B.R., Na Y.J., et al. Cannabidiol-induced apoptosis is mediated by activation of Noxa in human colorectal cancer cells. Cancer Lett. 2019;447:12\u201323. doi: 10.1016/j.canlet.2019.01.011.", "ArticleIdList": ["10.1016/j.canlet.2019.01.011", "30660647"]}, {"Citation": "Nabissi M., Morelli M.B., Amantini C., Liberati S., Santoni M., Ricci-Vitiani L., Pallini R., Santoni G. Cannabidiol stimulates Aml-1a-dependent glial differentiation and inhibits glioma stem-like cells proliferation by inducing autophagy in a TRPV2-dependent manner. Int. J. Cancer. 2015;137:1855\u20131869. doi: 10.1002/ijc.29573.", "ArticleIdList": ["10.1002/ijc.29573", "25903924"]}, {"Citation": "Massi P., Vaccani A., Ceruti S., Colombo A., Abbracchio M.P., Parolaro D. Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines. J. Pharmacol. Exp. Ther. 2004;308:838\u2013845. doi: 10.1124/jpet.103.061002.", "ArticleIdList": ["10.1124/jpet.103.061002", "14617682"]}, {"Citation": "Nabissi M., Morelli M.B., Santoni M., Santoni G. Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis. 2013;34:48\u201357. doi: 10.1093/carcin/bgs328.", "ArticleIdList": ["10.1093/carcin/bgs328", "23079154"]}, {"Citation": "Solinas M., Massi P., Cinquina V., Valenti M., Bolognini D., Gariboldi M., Monti E., Rubino T., Parolaro D. Cannabidiol, a Non-Psychoactive Cannabinoid Compound, Inhibits Proliferation and Invasion in U87-MG and T98G Glioma Cells through a Multitarget Effect. PLoS ONE. 2013;8:e76918. doi: 10.1371/journal.pone.0076918.", "ArticleIdList": ["10.1371/journal.pone.0076918", "PMC3804588", "24204703"]}, {"Citation": "Alharris E., Singh N.P., Nagarkatti P.S., Nagarkatti M. Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019;10:45\u201359. doi: 10.18632/oncotarget.26534.", "ArticleIdList": ["10.18632/oncotarget.26534", "PMC6343753", "30713602"]}, {"Citation": "Andradas C., Byrne J., Kuchibhotla M., Ancliffe M., Jones A.C., Carline B., Hii H., Truong A., Storer L.C.D., Ritzmann T.A., et al. Assessment of Cannabidiol and \u03949-Tetrahydrocannabiol in Mouse Models of Medulloblastoma and Ependymoma. Cancers. 2021;13:330. doi: 10.3390/cancers13020330.", "ArticleIdList": ["10.3390/cancers13020330", "PMC7829707", "33477420"]}, {"Citation": "Dall\u2019Stella P.B., Docema M.F.L., Maldaun M.V.C., Feher O., Lancellotti C.L.P. Case Report: Clinical Outcome and Image Response of Two Patients with Secondary High-Grade Glioma Treated With Chemoradiation, PCV, and Cannabidiol. Front. Oncol. 2019;8 doi: 10.3389/fonc.2018.00643.", "ArticleIdList": ["10.3389/fonc.2018.00643", "PMC6345719", "30713832"]}, {"Citation": "Ivanov V.N., Wu J., Wang T.J.C., Hei T.K. Inhibition of ATM kinase upregulates levels of cell death induced by cannabidiol and \u03b3-irradiation in human glioblastoma cells. Oncotarget. 2019;10:825\u2013846. doi: 10.18632/oncotarget.26582.", "ArticleIdList": ["10.18632/oncotarget.26582", "PMC6368233", "30783513"]}, {"Citation": "FDA and Cannabis: Research and Drug Approval Process.  [(accessed on 2 April 2021)]; Available online:  https://www.fda.gov/news-events/public-health-focus/fda-and-cannabis-research-and-drug-approval-process."}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "3", "Day": "24"}, {"Year": "2021", "Month": "4", "Day": "17"}, {"Year": "2021", "Month": "4", "Day": "19"}, {"Year": "2021", "Month": "4", "Day": "30", "Hour": "1", "Minute": "11"}, {"Year": "2021", "Month": "5", "Day": "1", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "5", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "4", "Day": "21"}], "PublicationStatus": "epublish", "ArticleIdList": ["33919010", "PMC8122338", "10.3390/ijms22094294", "ijms22094294"]}}], "PubmedBookArticle": []}